Phase‑3 results show a custom mRNA vaccine dramatically lowers melanoma relapse and death when paired with pembrolizumab, marking a potential shift in adjuvant care.
Researchers have unveiled the first personalised cancer vaccine to achieve a clear benefit in a phase-three study. The experimental product, called intismeran, is designed from each patient’s own tumour mutations and is administered alongside the checkpoint inhibitor pembrolizumab (Keytruda).
In a trial of 1,137 adults whose high-risk cutaneous melanoma was surgically removed, the combination reduced the chance of the disease returning or causing death by 42% over a median follow-up of 24.6 months.
How the trial was structured and what it measured
The INTerpath-001 study was a randomised, double-blind, placebo-controlled investigation conducted across multiple centres, including the Melanoma Institute Australia. Participants were allocated to receive either the personalised mRNA vaccine or a saline placebo, while all subjects received a year-long course of pembrolizumab.
The primary endpoint was recurrence-free survival, i.e., the time before any detectable melanoma re-appeared or the patient died from the disease.
At two years, 82.2% of vaccine recipients remained alive without melanoma, versus 70.0% in the pembrolizumab-only arm. Moreover, the risk of distant metastasis or death fell by 38% in the vaccine group. A pre-specified sensitivity analysis revealed that the survival advantage became most pronounced after the first six months, showing a 58% risk reduction beyond that point.
What makes the vaccine personalised
Each dose of intismeran is custom-manufactured after sequencing the excised tumour. Up to 34 tumour-specific neoantigens are identified, and synthetic mRNA strands encoding these targets are packaged into lipid nanoparticles. When injected, the mRNA instructs the patient’s cells to produce the neoantigen proteins, effectively training the immune system to recognise and attack any residual malignant cells that share those signatures.
Because the vaccine is bespoke, a short manufacturing window follows surgery while the tumour’s genetic profile is analysed. Patients then receive up to nine injections, spaced three weeks apart. This logistical nuance is a key consideration for health systems planning future rollout.
Safety profile and next steps
Adverse events were common but largely mild. Treatment-related side effects occurred in 95.8% of vaccine recipients and 90.0% of those on pembrolizumab alone. Grade 3 or higher events were comparable between groups (14.2% vs. 13.4%). The most frequent complaints were fever, injection-site pain and fatigue, with no new safety signals detected.
The investigators stress that the overall-survival data are still immature; the study continues to monitor whether the recurrence benefit translates into longer lives. If the trend holds, regulatory filings are expected next year, with companies hoping for approval shortly thereafter. However, the bespoke nature of the product may affect pricing and NHS adoption, a point highlighted by several independent experts.
Implications for the broader fight against cancer
Commentators see the melanoma results as a potential harbinger for personalised vaccines in other hard-to-treat tumours. Merck and Moderna are already testing intismeran-style approaches in kidney, bladder and lung cancers. Success in melanoma does not guarantee similar outcomes elsewhere, but the trial establishes a proof-of-concept that customised mRNA vaccines can augment existing immunotherapies.
For patients currently under surveillance after melanoma surgery, the findings underscore the importance of enrolment in clinical studies. Physicians are urged to discuss trial eligibility with eligible individuals, as the vaccine remains investigational and is not yet part of standard care.
